Blog de la recherche
Des résumés accessibles des nouvelles études sur le HSV, des résultats d’essais et des décisions réglementaires. Chaque article renvoie à sa source.
Fred Hutch’s Keith Jerome on the road to a herpes cure
The scientist leading the best-known HSV gene-therapy program sat down to talk cure research. Here’s the background that makes the conversation worth your time.
Lire le résumé
Moderna posts results for its therapeutic HSV‑2 vaccine
Results from the Phase 1/2 study of mRNA‑1608 in adults with recurrent genital herpes are now public. Here’s what the trial was designed to answer.
Lire le résumé
Long-acting herpes pills finish Phase 1b
Assembly Bio completed follow-up for its two helicase-primase inhibitors. The headline number: 94% fewer days of viral shedding than placebo.
Lire le résumé
FDA fast-tracks review of pritelivir
If approved, it would be the first new HSV treatment in more than 20 years. A decision is due by the end of 2026.
Lire le résumé
Gilead licenses Assembly Bio’s herpes program
After positive early data, one of the world’s largest antiviral companies takes over development of two long-acting herpes drugs.
Lire le résumé
A simpler, safer gene therapy for herpes
Fred Hutch reported that a streamlined gene-editing treatment removed 90% or more of HSV‑1 in mice, with fewer side effects.
Lire le résuméRecevez la prochaine actualité par e-mail
Un e-mail par avancée importante. Désinscription à tout moment.
Recevoir les actualités de la recherche
Votre prénom et votre e-mail. C’est tout.